Probiotic neoantigen delivery vectors for precision cancer immunotherapyAndrew Redenti, Nicholas Arpaia, Jongwon Im et al.|Nature|2024Cited by 164
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Carole B. Miller et al.|Haematologica|2013Cited by 162
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studiesVikas Gupta, Srđan Verstovšek, Claire Harrison et al.|Haematologica|2016Cited by 85
Probiotic neoantigen delivery vectors for precision cancer immunotherapyAndrew Redenti, Nicholas Arpaia, Jongwon Im et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 10